Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Dasatinib Versus Imatinib in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Not Achieved an Optimal Response to 3 Months of Imatinib Therapy: Dascern

Jorge E. Cortes, MD, Qian Jiang, MD, Jianxiang Wang, MD, Jianyu Weng, MD, Huanling Zhu, MD, Liu Xiaoli, MD, Andreas Hochhaus, MD, Dong-Wook Kim, MD PhD, Jerald Radich, MD, Michael R. Savona, MD, Patricia Martin Regueira, MD, Oumar Sy, PhD, Renuka Gurnani, BA, Giuseppe Saglio

Blood (2018) 132 (Supplement 1): 788.

https://doi.org/10.1182/blood-2018-99-111978

Published: 2018

Journal Articles

Patients' Perspectives on the Definition of Cure in Chronic Myeloid Leukemia: A US Based Survey

Blood (2018) 132 (Supplement 1): 5843.

https://doi.org/10.1182/blood-2018-99-114589

Published: 2018

Journal Articles

Cost-Effectiveness of Blinatumomab Versus Standard of Care in Adult Patients with Philadelphia-Chromosome-Negative B-Precursor Acute Lymphoblastic Leukemia in First Hematological Complete Remission (CR) with Minimal Residual Disease (MRD) from a US Payer Perspective

Thomas Delea, MBA, MSIA, Nicholas Despiegel, Diana Boyko, Jordan Amdahl, Ze Cong, PhD MS, Jerald Radich, MD

Blood (2018) 132 (Supplement 1): 4746.

https://doi.org/10.1182/blood-2018-99-115230

Published: 2018

Journal Articles

Characterization of Novel Subtypes in B Progenitor Acute Lymphoblastic Leukemia

Zhaohui Gu, PhD, Michelle L. Churchman, PhD, Kathryn G. Roberts, PhD, Ian Moore, MS, Xin Zhou, PhD, Joy Nakitandwe, PhD, Kohei Hagiwara, MD, Stephane Pelletier, PhD, Sebastian Gingras, PhD, Hartmut Berns, PhD, Debbie Payne-Turner, Ashley Hill, BS, Ilaria Iacobucci, PhD, Lei Shi, PhD, Stanley Pounds, PhD, Cheng Cheng, PhD, Deqing Pei, MS, Chunxu Qu, PhD, Meenakshi Devidas, PhD, Yunfeng Dai, PhD, Shalini C. Reshmi, PhD, Julie Gastier Foster, PhD, Elizabeth A. Raetz, MD, Michael J. Borowitz, MD PhD, Brent Wood, MD PhD, William L. Carroll, MD, Patrick Zweider McKay, MD PhD, Karen R. Rabin, MD PhD, Leonard A. Mattano, MD, Kelly W. Maloney, MD, Alessandro Rambaldi, MD PhD, Orietta Spinelli, PhD, Jerald Radich, MD, Mark D. Minden, MD PhD, Jacob M. Rowe, MD, Selina Luger, MD, Mark R. Litzow, MD, Martin S. Tallman, MD, Janis Recevskis, PhD, Yanming Zhang, Ravi Bhatia, MD, Jessica Kohlschmidt, PhD, Krzysztof Mrózek, MDPhD, Clara D. Bloomfield, MD, Wendy Stock, MD, Steven M. Kornblau, MD, Hagop M. Kantarjian, MD, Marina Y. Konopleva, MD PhD, William E. Evans, PharmD, Sima Jeha, MD, Ching-Hon Pui, MD, Jun J. Yang, PhD, Elisabeth M. Paietta, PhD, James R. Downing, MD, Mary V Relling, PharmD, Jinghui Zhang, Mignon L. Loh, MD, Stephen P. Hunger, MD, Charles G. Mullighan, MBBS, MD

Blood (2018) 132 (Supplement 1): 565.

https://doi.org/10.1182/blood-2018-99-111219

Published: 2018

Journal Articles

BCR-ABL Testing Frequency Lower Than NCCN Recommendations in Lab Network Review of CML Patients

Carol Smyth, MB, Jason Bhan, MD, Tatiana Sorokina, MSc, Niyati Parikh, MSc, Vivian Oehler, MD, Jerald Radich, MD

Blood (2014) 124 (21): 1807.

https://doi.org/10.1182/blood.V124.21.1807.1807

Published: 2014

Journal Articles

Single-Arm, Open-Label, Multicenter Study Of Deep Molecular Response (MR 4.5 ) With Nilotinib In Adult Patients (pts) With Newly Diagnosed Philadelphia Chromosome–Positive Chronic Myeloid Leukemia In Chronic Phase (CML-CP): ENESTnext Study Update

Michael Mauro, MD, Jerald Radich, MD, Jorge E. Cortes, MD, Shaker Dakhil, MD, Christopher Keir, MD, Sandy Yi, Martha Wadleigh, MD, Vivian G. Oehler, MD, Thomas Ervin, MD, Stuart Goldberg, MD, Michael Savona, MD, FACP

Blood (2013) 122 (21): 4015.

https://doi.org/10.1182/blood.V122.21.4015.4015

Published: 2013

Journal Articles

Patients With Philadelphia-Positive Leukemia With BCR-ABL Kinase Mutations Prior To Allogeneic Transplantation Predominantly Relapse With The Same Mutation

Daniel N. Egan, MD, Lan Beppu, Jerald Radich, MD

Blood (2013) 122 (21): 4043.

https://doi.org/10.1182/blood.V122.21.4043.4043

Published: 2013

Journal Articles

Prognostic Significance Of NPM1 mutations In The Absence Of FLT3 -ITD in Older Patients With AML: A SWOG Report

Fabiana Ostronoff, MD, Megan Othus, PhD, Soheil Meshinchi, MD, PhD, John E. Godwin, MD, MS, Kenneth J. Kopecky, PhD, Alan List, MD, Vivian G. Oehler, MD, Stephen Petersdorf, MD, Era L. Pogosova-Agadjanyan, Jerald Radich, MD, Cheryl L. Willman, MD, Frederick R. Appelbaum, MD, Derek L. Stirewalt, MD

Blood (2013) 122 (21): 1315.

https://doi.org/10.1182/blood.V122.21.1315.1315

Published: 2013

Journal Articles

NUP98/NSD1 Translocation Further Risk-Stratifies Patients With FLT3/ITD In Acute Myeloid Leukemia: A Report From Children’s Oncology Group and SWOG

Fabiana Ostronoff, MD, Megan Othus, PhD, Robert B. Gerbing, MA, Michael R. Loken, PhD, Susana C Raimondi, PhD, Betsy A. Hirsch, PhD, Beverly J. Lange, MD, Stephen Petersdorf, MD, Jerald Radich, MD, Frederick R. Appelbaum, MD, Alan S. Gamis, MD, MPH, Todd A. Alonzo, PhD, Soheil Meshinchi, MD, PhD

Blood (2013) 122 (21): 488.

https://doi.org/10.1182/blood.V122.21.488.488

Published: 2013

Journal Articles

Prevalence and Clinical Implications of N-RAS Mutations in Childhood AML – A Report From the Children's Oncology Group.

Jason N. Berman, MD, Robert B. Gerbing, PhD, Lillian Sung, MD, Kristen Miller, BS, Jessica A. Pollard, MD, Phoenix Ho, Derek Stirewalt, Jerald Radich, MD, Craig A. Hurwitz, MD, Nyla A. Heerema, PhD, Betsy Hirsch, MD, Susana C. Raimondi, PhD, Beverly Lange, MD, Alan S. Gamis, MD, Janet L. Franklin, MD, MPH, Todd A. Alonzo, PhD, Soheil Meshinchi, MD, PhD

Blood (2009) 114 (22): 3115.

https://doi.org/10.1182/blood.V114.22.3115.3115

Published: 2009

Journal Articles

Southwest Oncology Group Study S0530: A Phase 2 Trial of Clofarabine/ Cytarabine for Relapsed/ Refractory Acute Lymphocytic Leukemia.

Anjali Advani, MD, Holly Gundacker, MS, Olga Sala-Torra, MD, Jerald Radich, MD, Raymond Lai, MD, PhD, Marilyn L. Slovak, PhD, Jeffrey E Lancet, MD, Steve Coutre, MD, Robert K Stuart, MD, Martha P. Mims, MD, PhD, Patrick Stiff, MD, Frederick R. Appelbaum, MD

Blood (2009) 114 (22): 3094.

https://doi.org/10.1182/blood.V114.22.3094.3094

Published: 2009

Journal Articles

Dasatinib-Associated Major Molecular Responses Are Rapidly Achieved in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Following Resistance, Suboptimal Response, or Intolerance on Imatinib.

Andreas Hochhaus, MD, Martin C Müller, MD, Jerald Radich, MD, Susan Branford, Benjamin Hanfstein, MD, Philippe Rousselot, MD, PhD, Jeffrey H Lipton, MD, PhD, Eric Bleickardt, Ritwik Sinha, Timothy P Hughes, MD

Blood (2008) 112 (11): 1095.

https://doi.org/10.1182/blood.V112.11.1095.1095

Published: 2008

Journal Articles

Mathematical Simulation of BCR-ABL Real Time Quantitative Polymerase Chain Reaction (RQ-PCR) for Chronic Myeloid Leukemia (CML) Response Monitoring Provides Insight on the Basis of International Standardization.

Vi j ay Modur, MD, PhD, Dean C Bottino, PhD, Susan Branford, PhD, Tillmann Krahnke, PhD, Fabrizio Pane, MD, Marc Rudoltz, MD, Yu Jin, Timothy P Hughes, MD, Dong-Wook Kim, MD, PhD, Jerald Radich, MD, J. Carl Barrett, PhD

Blood (2008) 112 (11): 2124.

https://doi.org/10.1182/blood.V112.11.2124.2124

Published: 2008

Journal Articles

Gene Conversion Is a Late Event in Evolution of High Risk AML.

Soheil Meshinchi, MD, PhD, Jessica A. Pollard, MD, Karen D. Tsuchiya, MD, Derek A. Stirewalt, MD, Irwin D. Bernstein, MD, Jerald Radich, MD

Blood (2007) 110 (11): 207.

https://doi.org/10.1182/blood.V110.11.207.207

Published: 2007

Journal Articles

Hematologic and Cytogenetic Response Dynamics to Nilotinib (AMN107) Depend on the Type of BCR-ABL Mutations in Patients with Chronic Myelogeneous Leukemia (CML) after Imatinib Failure.

Andreas Hochhaus, MD, Philipp Erben, MD, Susan Branford, PhD, Jerald Radich, MD, D.W. Kim, MD, Giovanni Martinelli, MD, Giuseppe Saglio, MD, Martin C. Mueller, MD, Jana Hoffmann, Francesca Palandri, Simona Soverini, MD, Timothy Hughes, MD, Yaping Shou, MD PhD, Aaron Weitzman, MD, Michele Baccarani, MD

Blood (2006) 108 (11): 749.

https://doi.org/10.1182/blood.V108.11.749.749

Published: 2006

Journal Articles

Molecular Responses in Newly Diagnosed Chronic Myelocytic Leukemia (CML) Patients Treated with 800 mg Imatinib Daily: An Update from the RIGHT Trial Study Group.

Jorge Cortes, MD, Francis Giles, MD, August J. Salvado, MD, Karen McDougall, Jerald Radich, MD, Maher Albitar, MD, Bayard L. Powell, MD, Stuart Goldberg, MD, Hagop M. Kantarjian, MD

Blood (2006) 108 (11): 2149.

https://doi.org/10.1182/blood.V108.11.2149.2149

Published: 2006

Journal Articles

Interim Analysis of a Multicenter Trial of High Dose (HD) Imatinib in Newly Diagnosed Early Chronic Phase (CP) Patients (pt) with Chronic Myeloid Leukemia (CML).

Jorge Cortes, MD, Francis Giles, MD, August J. Salvado, MD, Karen McDougall, RN, Jerald Radich, MD, Mahir Albitar, MD, Bayard L. Powell, MD, Stuart Goldberg, MD, Hagop M. Kantarjian, MD, RIGHT Trial Study Group

Blood (2005) 106 (11): 1085.

https://doi.org/10.1182/blood.V106.11.1085.1085

Published: 2005

Journal Articles

Fc γ Receptor Polymorphisms Do Not Influence Progression Free Survival (PFS) of Follicular NHL Pateints Treated with Chop Followed by Rituximab (SWOG 9800).

David G. Maloney, MD, PhD, Barbara Pender-Smith, MS, Joseph M. Unger, MS, Rita M. Braziel, MD, Jerald Radich, MD, Oliver W. Press, MD, PhD, Thomas P. Miller, MD, Thomas M. Grogan, MD, Michael LeBlanc, PhD, Richard I. Fisher, MD

Blood (2004) 104 (11): 589.

https://doi.org/10.1182/blood.V104.11.589.589

Published: 2004

Journal Articles

Non-Myeloablative Allografting from HLA-Identical Sibling Donors for Treatment of CML.

Fabio R. Kerbauy, MD, Thoralf Lange, MD, Ted Gooley, PhD, Judith Shizuru, MD, Jerald Radich, MD, David G. Maloney, MD, Edward Agura, MD, Benedetto Bruno, MD, Elliot Epner, MD, Thomas Chauncey, MD, PhD, Karl Blume, MD, Rainer Storb, MD, Dietger Niederwieser, MD, Brenda M. Sandmaier, MD

Blood (2004) 104 (11): 2316.

https://doi.org/10.1182/blood.V104.11.2316.2316

Published: 2004

NARROW

Dasatinib Versus Imatinib in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Not Achieved an Optimal Response to 3 Months of Imatinib Therapy: Dascern

Patients' Perspectives on the Definition of Cure in Chronic Myeloid Leukemia: A US Based Survey

Cost-Effectiveness of Blinatumomab Versus Standard of Care in Adult Patients with Philadelphia-Chromosome-Negative B-Precursor Acute Lymphoblastic Leukemia in First Hematological Complete Remission (CR) with Minimal Residual Disease (MRD) from a US Payer Perspective

Characterization of Novel Subtypes in B Progenitor Acute Lymphoblastic Leukemia

BCR-ABL Testing Frequency Lower Than NCCN Recommendations in Lab Network Review of CML Patients

Single-Arm, Open-Label, Multicenter Study Of Deep Molecular Response (MR 4.5 ) With Nilotinib In Adult Patients (pts) With Newly Diagnosed Philadelphia Chromosome–Positive Chronic Myeloid Leukemia In Chronic Phase (CML-CP): ENESTnext Study Update

Patients With Philadelphia-Positive Leukemia With BCR-ABL Kinase Mutations Prior To Allogeneic Transplantation Predominantly Relapse With The Same Mutation

Prognostic Significance Of NPM1 mutations In The Absence Of FLT3 -ITD in Older Patients With AML: A SWOG Report

NUP98/NSD1 Translocation Further Risk-Stratifies Patients With FLT3/ITD In Acute Myeloid Leukemia: A Report From Children’s Oncology Group and SWOG

Prevalence and Clinical Implications of N-RAS Mutations in Childhood AML – A Report From the Children's Oncology Group.

Southwest Oncology Group Study S0530: A Phase 2 Trial of Clofarabine/ Cytarabine for Relapsed/ Refractory Acute Lymphocytic Leukemia.

Dasatinib-Associated Major Molecular Responses Are Rapidly Achieved in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Following Resistance, Suboptimal Response, or Intolerance on Imatinib.

Mathematical Simulation of BCR-ABL Real Time Quantitative Polymerase Chain Reaction (RQ-PCR) for Chronic Myeloid Leukemia (CML) Response Monitoring Provides Insight on the Basis of International Standardization.

Gene Conversion Is a Late Event in Evolution of High Risk AML.

Hematologic and Cytogenetic Response Dynamics to Nilotinib (AMN107) Depend on the Type of BCR-ABL Mutations in Patients with Chronic Myelogeneous Leukemia (CML) after Imatinib Failure.

Molecular Responses in Newly Diagnosed Chronic Myelocytic Leukemia (CML) Patients Treated with 800 mg Imatinib Daily: An Update from the RIGHT Trial Study Group.

Interim Analysis of a Multicenter Trial of High Dose (HD) Imatinib in Newly Diagnosed Early Chronic Phase (CP) Patients (pt) with Chronic Myeloid Leukemia (CML).

Fc γ Receptor Polymorphisms Do Not Influence Progression Free Survival (PFS) of Follicular NHL Pateints Treated with Chop Followed by Rituximab (SWOG 9800).

Non-Myeloablative Allografting from HLA-Identical Sibling Donors for Treatment of CML.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only